Sexual dysfunction. Female sexual arousal disorder
Conditions
Interventions
Intervention 1: Intervention group: For 8 weeks, each day one saffrotine capsule (15 mg saffron) and one saffradid capsule (15 mg saffron+ 50 mg vitamin E), produced by Green Plants of life Company. I
produced by Green Plants of life Company.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 49 Years
Inclusion criteria
Inclusion criteria: Literacy (to be able to fill out the questionnaires) Married women aged 15 to 49 years Sexual dysfunction (FSFI score of less than 28) Sexually active No sleep disorder (score 5 or less in Pittsburgh Sleep Quality Index)
Exclusion criteria
Exclusion criteria: Drug and alcohol addiction Known sensitivity to saffron Pregnancy The first six months after delivery in lactating women Severe depression or any other known psychological disorder Occurrence of any serious stressors (such as separation of parents, death of a first-degree relative) in the last 3 months Underlying diseases (heart, digestive, respiratory, epilepsy, hypertension, diabetes) according to self report Regular use of any drugs affecting one's sexual response (including anti hypertensive drugs, thiazide diuretics, antidepressants, antihistamines, barbiturates, narcotics, diazepines, amphetamines, cocaine, herbal remedies) Menopause Daily consumption of saffron Daily intake of vitamin E supplements Participation in another trial Obvious sexual dysfunction in husband (according to woman report) No use of an effective contraceptive method Willing to become pregnant in near future
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sexual function Score. Timepoint: At baseline, 4 and 8 weeks of intervention and 4 weeks after intervention. Method of measurement: Female sexual function questionnaire (FSFI). | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety. Timepoint: At baseline, 4 and 8 weeks of intervention and 4 weeks after intervention. Method of measurement: Depression, Anxiety and Stress Scale (DASS-21).;Depression. Timepoint: At baseline, 4 and 8 weeks of intervention and 4 weeks after intervention. Method of measurement: Depression, Anxiety and Stress Scale (DASS-21).;Stress. Timepoint: At baseline, 4 and 8 weeks of intervention and 4 weeks after intervention. Method of measurement: Depression, Anxiety and Stress Scale (DASS-21). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeideh Izadi
Tabriz University of Medical Sciences
Outcome results
None listed